Market revenue in 2021 | USD 1,708.3 million |
Market revenue in 2030 | USD 3,819.4 million |
Growth rate | 9.4% (CAGR from 2021 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Mammalian |
Historical data | 2017 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 63.84% in 2021. Horizon Databook has segmented the France biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.
As of 2022, France was ranked third among the EU nations and seventh across the globe in terms of economy, thus highlighting the market potential of the nation. Furthermore, supportive government initiatives such as Choose France event, which showcases the country’s economic appeal and encourages foreign investments in the country, are anticipated to further boost the market.
Furthermore, there are several specialized biopharmaceutical CROs and CMOs in France, such as Recipharm, Viant Medical, CELLforCURE, Minakem, Siegfried, Aenova, Eurofins CDMO, and PX' Therapeutics, which is contributing to the market growth.
In addition, in 2018, CELLforCURE, a French CMO, entered into an agreement with Novartis for producing new CAR-T therapies. Such collaborations are anticipated to fuel the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France biopharmaceutical cmo and cro market , including forecasts for subscribers. This country databook contains high-level insights into France biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account